<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1809234223
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rybrevant 350 mg per 7 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMIVANTAMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5962.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Cilag AG, Schaffhausen, Switzerland" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Cilag AG, Schaffhausen, Switzerland
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Rybrevant is</strong></p><p>Rybrevant is a cancer medicine. It contains the active substance &lsquo;amivantamab&rsquo;, which is an antibody (type of protein) designed to recognise and attach to specific targets in the body.</p><p>&nbsp;</p><p><strong>What Rybrevant </strong><strong>is used for</strong></p><p>Rybrevant is used in adults with a type of lung cancer called &lsquo;non‑small cell lung cancer&rsquo;. It is used when the cancer has spread to other parts of your body and has gone through certain changes in a gene called &lsquo;EGFR&rsquo;.</p><p>Rybrevant can be prescribed for you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with chemotherapy after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as the first medicine you receive for your cancer in combination with chemotherapy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when chemotherapy is no longer working against your cancer.</p><p>&nbsp;</p><p><strong>How Rybrevant works</strong></p><p>The active substance in Rybrevant, amivantamab, targets two proteins found on cancer cells:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epidermal growth factor receptor (EGFR), and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mesenchymal‑epithelial transition factor (MET).</p><p>This medicine works by attaching to these proteins. This may help to slow or stop your lung cancer from growing. It may also help to reduce the size of the tumour.</p><p>&nbsp;</p><p>Rybrevant may be given in combination with other anti‑cancer medicines. It is important that you also read the package leaflets for these other medicines. If you have any questions about these medicines, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Rybrevant if</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to amivantamab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>Do not use this medicine if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Tell your doctor or nurse before you are given Rybrevant if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have suffered from inflammation of your lungs (a condition called &lsquo;interstitial lung disease&rsquo; or &lsquo;pneumonitis&rsquo;).</p><p>&nbsp;</p><p><strong>Tell your doctor or nurse straight away while taking this medicine if you get any of the following side effects (see section&nbsp;4 for more information):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any side effect while the medicine is being given into your vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden difficulty in breathing, cough, or fever that may suggest inflammation of the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin problems. To reduce the risk of skin problems, keep out of the sun, wear protective clothing, apply sunscreen, and use moisturisers regularly on your skin and nails while taking this medicine. You will need to continue doing this for 2&nbsp;months after you stop treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye problems. If you have vision problems or eye pain contact your doctor or nurse straight away. If you use contact lenses and have any new eye symptoms, stop using contact lenses and tell your doctor straight away.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children or young people below 18&nbsp;years of age. This is because it is not known whether the medicine is safe and effective in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Rybrevant</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>Contraception</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you could become pregnant, you must use effective contraception during Rybrevant treatment and for 3&nbsp;months after stopping treatment.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or nurse before you are given this medicine if you are pregnant, think you might be pregnant, or are planning to have a baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is possible that this medicine may harm an unborn baby. If you become pregnant while being treated with this medicine, tell your doctor or nurse straight away. You and your doctor will decide if the benefit of having the medicine is greater than the risk to your unborn baby.</p><p>&nbsp;</p><p><strong>Breast‑feeding</strong></p><p>It is not known if Rybrevant passes into breast milk. Ask your doctor for advice before being given this medicine. You and your doctor will decide if the benefit of breast‑feeding is greater than the risk to your baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>If you feel tired, feel dizzy, or if your eyes are irritated or vision is affected after taking Rybrevant, do not drive or use machinery.</p><p>&nbsp;</p><p><strong>Rybrevant contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;. However, before Rybrevant is given to you, it may be mixed with a solution that contains sodium. Talk to your doctor if you are on a low salt diet.</p><p>&nbsp;</p><p><strong>Rybrevant contains polysorbate</strong></p><p>This medicine contains 0.6&nbsp;mg of polysorbate 80 in each mL, which is equivalent to 4.2&nbsp;mg per 7&nbsp;mL vial. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>Your doctor will work out the correct dose of Rybrevant for you. The dose of this medicine will depend on your body weight at the start of your therapy. You will be treated with Rybrevant once every 2 or 3 weeks according to the treatment your doctor decides for you.</p><p>&nbsp;</p><p>The recommended dose of Rybrevant every 2&nbsp;weeks is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1050&nbsp;mg if you weigh less than 80&nbsp;kg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1400&nbsp;mg if you weigh more than or equal to 80&nbsp;kg.</p><p>&nbsp;</p><p>The recommended dose of Rybrevant every 3&nbsp;weeks is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1400&nbsp;mg for the first 4&nbsp;doses and 1750&nbsp;mg for subsequent doses if you weigh less than 80&nbsp;kg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1750&nbsp;mg for the first 4&nbsp;doses and 2100&nbsp;mg for subsequent doses if you weigh more than or equal to 80&nbsp;kg.</p><p>&nbsp;</p><p><strong>How the medicine is given</strong></p><p>This medicine will be given to you by a doctor or nurse. It is given as a drip into a vein (&lsquo;intravenous infusion&rsquo;) over several hours.</p><p>&nbsp;</p><p>Rybrevant is given as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; once a week for the first 4&nbsp;weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; then once every 2&nbsp;weeks starting at week&nbsp;5 or once every 3&nbsp;weeks starting at week&nbsp;7, for as long as you keep getting benefit from the treatment.</p><p>&nbsp;</p><p>In the first week, your doctor will give you the Rybrevant dose split over two days.</p><p>&nbsp;</p><p><strong>Medicines given during treatment with Rybrevant</strong></p><p>Before each infusion of Rybrevant, you will be given medicines which help lower the chance of infusion‑related reactions. These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for an allergic reaction (antihistamines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for inflammation (corticosteroids)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fever (such as paracetamol).</p><p>&nbsp;</p><p>You may also be given additional medicines based on any symptoms you may experience.</p><p>&nbsp;</p><p><strong>If you are given more Rybrevant</strong> <strong>than you should</strong></p><p>This medicine will be given by your doctor or nurse. In the unlikely event that you are given too much (an overdose), your doctor will check you for side effects.</p><p><em>&nbsp;</em></p><p><strong>If you forget your appointment to have Rybrevant</strong></p><p>It is very important to go to all your appointments. If you miss an appointment, make another one as soon as possible.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Tell your doctor or nurse straight away if you notice the following serious side effects:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of a reaction to the infusion - such as chills, feeling short of breath, feeling sick (nausea), flushing, chest discomfort, and vomiting while the medicine is being given. This can happen especially with the first dose. Your doctor may give you other medicines, or the infusion may need to be slowed down or stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin problems - such as rash (including acne), infected skin around the nails, dry skin, itching, pain, and redness. Tell your doctor if your skin or nail problems get worse.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye problems - such as dry eye, swollen eyelid, itchy eyes, problems with vision, growth of eyelashes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of an inflammation in the lungs - such as sudden difficulty in breathing, cough, or fever. This could lead to permanent damage (&lsquo;interstitial lung disease&rsquo;). Your doctor may wish to stop Rybrevant if you get this side effect.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed cornea (front part of the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation inside the eye that may affect vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life‑threatening rash with blisters and peeling skin over much of the body (toxic epidermal necrolysis).</p><p>&nbsp;</p><p>The following side effects have been reported in clinical studies with Rybrevant when given alone:</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Tell your doctor if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of the protein &lsquo;albumin&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid build up in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sores in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation or diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the liver enzyme &lsquo;alanine aminotransferase&rsquo; in the blood, a possible sign of liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;aspartate aminotransferase&rsquo; in the blood, a possible sign of liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage in arms and legs causing pain or numbness, burning and tingling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;alkaline phosphatase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint pain<sup> </sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of calcium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding (Hemorrhage)</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of magnesium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhoids</p><p>&nbsp;</p><p>The following side effects have been reported in clinical studies with Rybrevant in combination with chemotherapy:</p><p><strong>Other side effects</strong></p><p>Tell your doctor if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of &lsquo;platelets&rsquo;(cells that help blood to clot)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the veins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sores in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid build up in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of the protein &lsquo;albumin&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the liver enzyme &lsquo;alanine aminotransferase&rsquo; in the blood, a possible sign of liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;aspartate aminotransferase&rsquo; in the blood, a possible sign of liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of magnesium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of calcium in the blood</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;alkaline phosphatase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhoids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rybrevant will be stored at the hospital or clinic.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Chemical and physical in‑use stability has been demonstrated for 10&nbsp;hours at 15&deg;C to 25&deg;C in room light. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in‑use storage times and conditions are the responsibility of the user.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Rybrevant</strong> <strong>contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The active substance is amivantamab. One mL of concentrate for solution for infusion contains 50&nbsp;mg of amivantamab. One vial of 7&nbsp;mL concentrate contains 350&nbsp;mg of amivantamab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are ethylenediaminetetraacetic acid (EDTA), L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate&nbsp;80, sucrose, and water for injections (see section&nbsp;2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Rybrevant is a concentrate for solution for infusion and is a colourless to pale yellow liquid. This medicine is available in a carton pack containing 1 glass vial of 7 mL of concentrate.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Cilag AG</p><p>Hochstrasse 201</p><p>8200 Schaffhausen</p><p>Switzerland</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                To contact us, go to www.janssen.com/contact-us

This leaflet was last revised in22 August 2024. 
	

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو رايبريفانت</strong></p><p dir="RTL">رايبريفانت هو دواء لعلاج السرطان. ويحتوي على المادة الفعالة &quot; أميفانتاماب&quot;، وهو جسم مضاد (نوع من البروتين) مصمم للتعرف على أهداف محددة في الجسم والارتباط بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استخدام رايبريفانت</strong></p><p dir="RTL">يستخدم رايبريفانت للبالغين المصابين بأحد أنواع سرطان الرئة يطلق عليه &quot;سرطان الرئة ذي الخلايا غير الصغيرة&quot;. يتم استخدامه عند انتشار السرطان إلى أجزاء أخرى من الجسم وخضوعه لتغييرات معينة&nbsp; في جين يسمى مستقبل عامل نمو البشرة &quot;EGFR&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن وصف دواء رايبريفانت لك: بالاقتران مع العلاج الكيميائي بعد فشل العلاج السابق، بما في ذلك مثبطات التيروزين كيناز (TKI) لمُستقبل عامل نمو البشرة (EGFR).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كأول دواء تتلقاه لعلاج السرطان لديك مع العلاج الكيميائي، أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما يصبح العلاج الكيميائي غير فعّال ضد السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آلية عمل رايبريفانت</strong></p><p dir="RTL">تستهدف المادة الفعالة في رايبريفانت، أميفانتاماب، بروتينين موجودين بالخلايا السرطانية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستقبل عامل نمو البشرة (EGFR)، و</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عامل التحول بين اللحمة المتوسطة والظهارية (MET).</p><p dir="RTL">يعمل هذا الدواء من خلال الارتباط بهذين البروتينين. ويمكن أن يساعد ذلك في إبطاء نمو سرطان الرئة أو إيقاف نموه. ويمكن أن يساعد أيضًا في تقليل حجم الورم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء رايبريفانت إلى جانب أدوية أخرى مضادة للسرطان. من المهم أيضًا قراءة النشرات الداخلية لهذه الأدوية الأخرى. إذا كانت لديك أي أسئلة حول هذه الأدوية، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم رايبريفانت إذا</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنت تعاني من حساسية لمادة أميفانتاماب أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6)</p><p dir="RTL">لا تستخدم هذا الدواء إذا كان ينطبق عليك ما سبق. إذا لم تكن متأكدًا، تحدث إلى طبيبك أو ممرضتك قبل أن تُعطى هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك قبل أن تُعطى رايبريفانت إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت من التهاب برئتيك (حالة تسمى &quot;مرض الرئة الخلالي&quot; أو &quot;الالتهاب الرئوي&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو ممرضتك على الفور أثناء تناول هذا الدواء إذا كنت تعاني من أي من الآثار الجانبية التالية (انظر القسم </strong><strong>4</strong><strong> لمزيد من المعلومات):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أثر جانبي أثناء إعطاء الدواء في الوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة مفاجئة في التنفس أو سعال أو حمى، ما قد يشير إلى التهاب في الرئتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الجلد. لتقليل مخاطر مشاكل الجلد، يجب الابتعاد عن أشعة الشمس، وارتداء ملابس واقية، واستخدام واقي الشمس، واستخدام المرطبات بانتظام على البشرة والأظافر أثناء تناول هذا الدواء. ستحتاج إلى الاستمرار في القيام بذلك لمدة شهرين بعد التوقف عن العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل العيون. إذا كنت تعاني من مشاكل في الرؤية أو ألم بالعين، اتصل بطبيبك أو ممرضتك على الفور. إذا كنت تستخدم العدسات اللاصقة وظهرت لديك أي أعراض جديدة بالعين، فتوقف عن استخدام العدسات اللاصقة وأخبر طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يوصف هذا الدواء للأطفال أو الشباب الذين تقل أعمارهم عن 18 عامًا. وذلك لأنه من غير المعروف ما إذا كان الدواء آمنًا وفعالًا في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ورايبريفانت</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>منع الحمل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من الممكن أن تصبحي حاملاً، فيجب عليك استخدام وسيلة فعالة لمنع الحمل أثناء العلاج باستخدام رايبريفانت ولمدة 3 أشهر بعد التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبك أو ممرضتك قبل بدء استخدام هذا الدواء إذا كنت حاملاً، أو تعتقدين أنك حامل، أو تخططين للإنجاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الممكن أن يسبب هذا الدواء ضررًا للجنين. إذا أصبحتِ حاملاً أثناء العلاج بهذا الدواء، يجب إخبار طبيبك أو ممرضتك على الفور. ستقررين أنتِ وطبيبك ما إذا كانت فائدة استخدام الدواء أكبر من المخاطر التي سيتعرض لها الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">ليس من المعروف ما إذا كان رايبريفانت ينتقل إلى لبن الأم. اسألي طبيبك للحصول على المشورة قبل بدء استخدام هذا الدواء. ستقررين أنتِ وطبيبك ما إذا كانت فائدة الرضاعة الطبيعية أكبر من المخاطر التي سيتعرض لها طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">في حال الشعور بالتعب، أو الدوار، أو تهيج العينين أو تأثر الرؤية بعد تناول رايبريفانت، فتجنب قيادة السيارة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي رايبريفانت على الصوديوم</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من 1 مليمول من الصوديوم (23 مجم) في كل جرعة، أي أنه &quot;خالٍ من الصوديوم&quot; تقريبًا. ومع ذلك، قبل إعطاء رايبريفانت لك، يمكن مزجه بمحلول يحتوي على الصوديوم. تحدث إلى طبيبك إذا كنت تتبع نظامًا غذائيًا قليل الملح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي رايبريفانت على بوليسوربات</strong></p><p dir="RTL">يحتوي هذا الدواء على 0.6 مجم من بولي سوربات 80 في كل مل، وهو ما يعادل 4.2 مجم لكل قنينة سعة 7 مل. قد يسبب البولي سوربات ردود فعل تحسسية. أخبر طبيبك إذا كنت تعاني من أي حساسية معروفة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة المعطاة</strong></p><p dir="RTL">سيحدد طبيبك الجرعة المناسبة من رايبريفانت لك. ستعتمد جرعة هذا الدواء على وزن جسمك في بداية العلاج. ستتلقى العلاج بدواء رايبريفانت مرة كل أسبوعين أو ثلاثة أسابيع وفقًا للعلاج الذي يقرره طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من رايبريفانت كل أسبوعين هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1050 مجم إذا كان وزنك أقل من 80 كجم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1400 مجم إذا كان وزنك أكبر من أو يساوي 80 كجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها من رايبريفانت كل 3 أسابيع هي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1400&nbsp;مجم للجرعات الأربع الأولى و1750 مجم للجرعات اللاحقة إذا كان وزنك أقل من 80 كجم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1750 مجم للجرعات الأربع الأولى و2100 مجم للجرعات اللاحقة إذا كان وزنك أكثر من أو يساوي 80 كجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء الدواء</strong></p><p dir="RTL">سيعطيك الطبيب أو الممرضة هذا الدواء. يتم إعطاؤه بالتنقيط في الوريد (&quot;التسريب الوريدي&quot;) على مدى عدة ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء رايبريفانت على النحو التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرة واحدة في الأسبوع خلال أول 4 أسابيع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم مرة كل أسبوعين بدءًا من الأسبوع الخامس أو مرة كل 3 أسابيع بدءًا من الأسبوع السابع، طالما أنك تستفيد من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأسبوع الأول، سوف يعطيك الطبيب جرعة رايبريفانت مقسمة على يومين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التي تعطى أثناء العلاج برايبريفانت</strong></p><p dir="RTL">قبل كل تسريب وريدي لرايبريفانت، ستحصل على أدوية تساعد على تقليل فرصة حدوث تفاعلات مرتبطة بالتسريب الوريدي. وهذه قد تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لرد الفعل التحسسي (مضادات الهيستامين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للالتهاب (الكورتيكوستيرويدات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الحمى (مثل الباراسيتامول)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد توصف لك أيضًا على أدوية إضافية بناءً على أي أعراض قد تشعر بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك جرعة زائدة من رايبريفانت </strong></p><p dir="RTL">سيعطيك الطبيب أو الممرضة هذا الدواء. في الحالة المستبعدة لتلقي جرعة كبيرة للغاية (جرعة زائدة)، سيراقبك طبيبك تحسبًا لحدوث أي آثار جانبية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>إذا نسيت موعدك لتلقي رايبريفانت</strong></p><p dir="RTL">من المهم جدًا أن تحضر جميع مواعيدك. إذا فاتك موعد، فحدد موعدًا آخر في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، فيمكنك سؤال الطبيب أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية، لكن ليس بالضرورة أن يُصاب بها جميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL">أخبر طبيبك أو ممرضتك على الفور إذا لاحظت الآثار الجانبية الخطيرة التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات رد فعل تجاه التسريب - مثل القشعريرة، الشعور بضيق في التنفس، الشعور بالغثيان، الاحمرار، الشعور بعدم الراحة في الصدر، والقيء أثناء إعطاء الدواء. يمكن أن يحدث هذا خاصة مع الجرعة الأولى. قد يصف لك طبيبك أدوية أخرى، وقد تحتاج إلى إبطاء التسريب الوريدي أو إيقافه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الجلد - مثل الطفح الجلدي (بما في ذلك حب الشباب) وإصابة الجلد حول الأظافر وجفاف الجلد والحكة والألم والاحمرار. أخبر طبيبك إذا كانت مشاكل بشرتك أو أظافرك تزداد سوءًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا واحدًا على الأكثر من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في العين - مثل جفاف العين، تورم الجفن، حكة في العين، مشاكل في الرؤية، نمو الرموش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات التهاب في الرئتين - مثل صعوبة مفاجئة في التنفس أو سعال أو حمى. يمكن أن يؤدي ذلك إلى حدوث ضرر دائم (&quot;مرض الرئة الخلالي&quot;). قد يرغب طبيبك في إيقاف رايبريفانت إذا حدث لك هذا التأثير الجانبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب شخصًا واحدًا على الأكثر من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القرنية (الجزء الأمامي من العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب داخل العين قد يؤثر على الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يهدد الحياة مع ظهور بثور وتقشير الجلد في معظم أجزاء الجسم (انحلال البشرة النخري السمي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية في الدراسات السريرية مع دواء رايبريفانت عند استخدامه كعلاج وحيد:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">أخبر الطبيب إذا لاحظت حدوث أيّ من الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بروتين &quot;الألبومين&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم ناجم عن تراكم السوائل في الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات بالفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك أو الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية للطعام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم الكبد &quot;<strong> </strong>ناقلة أمين الألانين &quot; بالدم، وهي علامة محتملة لحدوث مشاكل بالكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم &quot; ناقلة أمين الأسبارتات &quot; بالدم، وهي علامة محتملة لحدوث مشاكل بالكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب في اليدين والرجلين مسبباً ألم أو تنميل وحرقة ووخز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم &quot; الفوسفاتاز القلوي &quot; بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الكالسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف (النزف)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا واحدًا على الأكثر من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى المغنيسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البواسير</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية في الدراسات السريرية مع دواء رايبريفانت عند استخدامه مع العلاج الكيميائي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">أخبر طبيبك إذا لاحظت أيًّا من الآثار الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا</strong> (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع من خلايا الدم البيضاء (قلة العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد &quot;الصفائح الدموية&quot; (الخلايا التي تساعد على تجلط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم في الأوردة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم الناجم عن تراكم السوائل في الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بروتين &quot;الألبومين&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم الكبد &quot;ناقلة أمين الألانين&quot; في الدم، وهي علامة على احتمالية وجود مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot; ناقلة أمين الأسبارتات&quot; في الدم، وهي علامة على احتمالية وجود مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى المغنيسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الكالسيوم في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تصيب شخصًا واحدًا على الأكثر من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot;الفوسفاتاز القلوي&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البواسير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ طبيبك أو&nbsp; الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم تخزين رايبريفانت في المستشفى أو العيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول الأطفال وأنظارهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المبين على العلبة الكرتونية والقنينة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام لمدة 10 ساعات عند درجة حرارة تتراوح بين 15 إلى 25 درجة مئوية في ضوء الغرفة. من وجهة نظر ميكروبيولوجية، ما لم تكن طريقة التخفيف تمنع حدوث خطر التلوث الميكروبي، فيجب استخدام المنتج على الفور. في حالة عدم الاستخدام على الفور، يتحمل المستخدم مسؤولية أوقات التخزين وظروفه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (من 2 إلى 8 درجات مئوية). لا يُجَمَّد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجوز التخلّص من الأدوية بإلقائها في الفضلات السائلة أو المخلفات المنزلية. سيتخلص أخصائي الرعاية الصحية من أي أدوية لم تعد مستخدمة. فهذه الإجراءات من شأنها المساعدة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي محتويات رايبريفانت </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أميفانتاماب. يحتوي كل مل من المركز لمحلول التسريب على 50 مجم من أميفانتاماب. تحتوي قنينة واحدة من مركز 7 مل على 350 مجم من أميفانتاماب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ثنائي أمين الإيثيلين رباعي حمض الأسيتيك (EDTA)، إل - هيستيدين، إل - هيستيدين هيدروكلوريد مونوهيدرات، إل - ميثيونين، بولي سوربات 80، سكروز، وماء للحقن (انظر القسم 2).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو </strong><strong>شكل رايبريفانت ووصفه، وعلى ماذا تحتوي العبوة</strong></p><p dir="RTL">رايبريفانت هو مركز لمحلول التسريب الوريدي وهو سائل عديم اللون ويميل إلى أصفر شاحب. يتوفر هذا الدواء في علبة كرتونية تحتوي على قنينة زجاجية واحدة سعة 7 مل من المركز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">جانسن سيلاج انترناشونال ان في</p><p dir="RTL">تورنهوتسويج 30</p><p dir="RTL">بي-2340 بيرس</p><p dir="RTL">بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">سيلاج إيه جي</p><p dir="RTL">هوتشسراسا 201</p><p dir="RTL">8200 تشافهاوزن</p><p dir="RTL">سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            للتواصل معنا، يُرجى زيارة موقعنا الإلكتروني  www.janssen.com/contact-us

	تمت آخر مراجعة لهذه النشرة في 22 أغسطس 2024. 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rybrevant 350 mg concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One mL of concentrate for solution for infusion contains 50 mg amivantamab.
One 7 mL vial contains 350 mg of amivantamab.

Amivantamab is a fully human Immunoglobulin G1 (IgG1) based bispecific antibody directed against the epidermal growth factor (EGF) and mesenchymal epidermal transition (MET) receptors, produced by a mammalian cell line (Chinese Hamster Ovary [CHO]) using recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

The solution is colourless to pale yellow, with a pH of 5.7 and an osmolality of approximately 310 mOsm/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rybrevant is indicated:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non‑small cell lung cancer (NSCLC) with EGFR Exon&nbsp;19 deletions or Exon&nbsp;21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced NSCLC with activating EGFR Exon&nbsp;20 insertion mutations.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon&nbsp;20 insertion mutations, after failure of platinum‑based therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Rybrevant should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p>&nbsp;</p><p>Rybrevant should be administered by a healthcare professional with access to appropriate medical support to manage infusion‑related reactions (IRRs) if they occur.</p><p>&nbsp;</p><p>Before initiation of Rybrevant therapy, EGFR mutation status in tumour tissue or plasma specimens must be established using a validated test method. If no mutation is detected in a plasma specimen, tumour tissue should be tested if available in sufficient amount and quality due to the potential for false negative results using a plasma‑test. Testing may be performed at any time from initial diagnosis until the initiation of therapy; testing does not need to be repeated once EGFR mutation status has been established (see section&nbsp;5.1).</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>Premedications should be administered to reduce the risk of IRRs with Rybrevant (see below &ldquo;Dose modifications&rdquo; and &ldquo;Recommended concomitant medicinal products&rdquo;).</p><p>&nbsp;</p><p><em>Every 3&nbsp;weeks</em></p><p>The recommended dosages of Rybrevant, when used in combination with carboplatin and pemetrexed, is provided in Table&nbsp;1 (see below &ldquo;Infusion rates&rdquo; and Table&nbsp;5).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;1: Recommended dosage of Rybrevant every 3&nbsp;weeks</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight at baseline<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Rybrevant dose</strong></p></td><td style="vertical-align:top"><p><strong>Schedule</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Less than 80&nbsp;kg</p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td style="vertical-align:top"><p>Weekly (total of 4&nbsp;doses) from Weeks 1 to 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;1 - split infusion on Day&nbsp;1 and Day&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weeks&nbsp;2 to 4 - infusion on Day&nbsp;1</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td style="vertical-align:top"><p>Every 3&nbsp;weeks starting at Week&nbsp;7 onwards</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Greater than or equal to 80&nbsp;kg</p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td style="vertical-align:top"><p>Weekly (total of 4&nbsp;doses) from Weeks 1 to 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;1 - split infusion on Day&nbsp;1 and Day&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weeks&nbsp;2 to 4 - infusion on Day&nbsp;1</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>2100&nbsp;mg</p></td><td style="vertical-align:top"><p>Every 3&nbsp;weeks starting at Week&nbsp;7 onwards</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments not required for subsequent body weight changes.</p></td></tr></tbody></table><p>&nbsp;</p><p>When used in combination with carboplatin and pemetrexed, Rybrevant should be administered after carboplatin and pemetrexed in the following order: pemetrexed, carboplatin and then Rybrevant. See section&nbsp;5.1 and the manufacturer&rsquo;s prescribing information for dosing instructions for carboplatin and pemetrexed.</p><p>&nbsp;</p><p><em>Every 2&nbsp;weeks</em></p><p>The recommended dosages of Rybrevant monotherapy is provided in Table&nbsp;2 (see below &ldquo;Infusion rates&rdquo; and Table&nbsp;6).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;2: Recommended dosage of Rybrevant every 2&nbsp;weeks</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body weight at baseline<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Rybrevant dose</strong></p></td><td style="vertical-align:top"><p><strong>Schedule</strong></p></td><td style="vertical-align:top"><p><strong>Number of vials</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Less than 80&nbsp;kg</p></td><td rowspan="2"><p>1050&nbsp;mg</p></td><td style="vertical-align:top"><p>Weekly (total of 4&nbsp;doses) from weeks 1 to 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;1 - split infusion on Day&nbsp;1 and Day&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weeks&nbsp;2 to 4 - infusion on Day&nbsp;1</p></td><td rowspan="2"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Every 2&nbsp;weeks starting at Week&nbsp;5 onwards</p></td></tr><tr><td style="vertical-align:top"><p>Greater than or equal to 80&nbsp;kg</p></td><td rowspan="2"><p>1400&nbsp;mg</p></td><td style="vertical-align:top"><p>Weekly (total of 4&nbsp;doses) from Weeks 1 to 4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Week&nbsp;1 - split infusion on Day&nbsp;1 and Day&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weeks&nbsp;2 to 4 - infusion on Day&nbsp;1</p></td><td rowspan="2"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Every 2&nbsp;weeks starting at Week&nbsp;5 onwards</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustments not required for subsequent body weight changes.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Duration of treatment</u></em></p><p>It is recommended that patients are treated with Rybrevant until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><em><u>Missed dose</u></em></p><p>If a planned dose is missed, the dose should be administered as soon as possible and the dosing schedule should be adjusted accordingly, maintaining the treatment interval.</p><p><em>&nbsp;</em></p><p><em><u>Dose modifications</u></em></p><p>Dosing should be interrupted for Grade&nbsp;3 or 4 adverse reactions until the adverse reaction resolves to &le;&nbsp;Grade&nbsp;1 or baseline. If an interruption is 7&nbsp;days or less, restart at the current dose. If an interruption is longer than 7&nbsp;days, it is recommended restarting at a reduced dose as presented in Table&nbsp;3. See also specific dose modifications for specific adverse reactions below Table&nbsp;3.</p><p>&nbsp;</p><p><strong>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Dose at which the adverse reaction occurred</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose after 1<sup>st</sup> interruption for adverse reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose after 2<sup>nd</sup> interruption for adverse reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose after 3<sup>rd</sup> interruption for adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td style="vertical-align:top"><p>700&nbsp;mg</p></td><td style="vertical-align:top"><p>350&nbsp;mg</p></td><td rowspan="4"><p>Discontinue Rybrevant</p></td></tr><tr><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td style="vertical-align:top"><p>700&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>2100&nbsp;mg</p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Infusion‑related reactions</em></p><p>Infusion should be interrupted at the first sign of IRRs. Additional supportive medicinal products (e.g., additional glucocorticoids, antihistamine, antipyretics and antiemetics) should be administered as clinically indicated (see section&nbsp;4.4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade&nbsp;1‑3 (mild‑severe): Upon recovery of symptoms, resume infusion at 50% of the previous rate. If there are no additional symptoms, the rate may be increased per the recommended infusion rate (see Tables&nbsp;5 and 6). Concomitant medicinal products should be administered at the next dose (including dexamethasone (20&nbsp;mg) or equivalent (see Table&nbsp;4).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade&nbsp;3 or Grade&nbsp;4 (life‑threatening): Permanently discontinue Rybrevant.</p><p>&nbsp;</p><p><em>Skin and nail reactions</em></p><p>If the patient develops a Grade&nbsp;1-2 skin or nail reaction, supportive care should be initiated; if there is no improvement after 2&nbsp;weeks, dose reduction should be considered for persistent Grade&nbsp;2 rash (see Table&nbsp;3). If the patient develops a Grade&nbsp;3 skin or nail reaction, supportive care should be initiated, and interruption of Rybrevant should be considered until the adverse reaction improves. Upon recovery of the skin or nail reaction to &le;&nbsp;Grade&nbsp;2, Rybrevant should be resumed at a reduced dose. If the patient develops Grade&nbsp;4 skin reactions, permanently discontinue Rybrevant (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Interstitial lung disease</em></p><p>Rybrevant should be withheld if interstitial lung disease (ILD) or ILD-like adverse reactions (pneumonitis) is suspected. If the patient is confirmed to have ILD or ILD‑like adverse reactions (e.g., pneumonitis), permanently discontinue Rybrevant (see section&nbsp;4.4).</p><p><em>&nbsp;</em></p><p><u>Recommended concomitant medicinal products</u></p><p>Prior to infusion (Week&nbsp;1, Days&nbsp;1 and 2), antihistamines, antipyretics, and glucocorticoids should be administered to reduce the risk of IRRs (see Table&nbsp;4). For subsequent doses, antihistamines and antipyretics are required to be administered. Glucocorticoids should also be re‑initiated after prolonged dose interruptions. Antiemetics should be administered as needed.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4"><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dosing schedule of premedications</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Premedication</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose</strong></p></td><td style="vertical-align:bottom"><p><strong>Route of administration</strong></p></td><td style="vertical-align:bottom"><p><strong>Recommended dosing window prior to Rybrevant administration</strong></p></td></tr><tr><td rowspan="2"><p><strong>Antihistamine<sup>*</sup></strong></p></td><td rowspan="2"><p>Diphenhydramine (25 to 50&nbsp;mg) or equivalent</p></td><td><p>Intravenous</p></td><td><p>15 to 30&nbsp;minutes</p></td></tr><tr><td><p>Oral</p></td><td><p>30 to 60&nbsp;minutes</p></td></tr><tr><td rowspan="2"><p><strong>Antipyretic<sup>*</sup></strong></p></td><td rowspan="2"><p>Paracetamol/Acetaminophen (650 to 1000&nbsp;mg)</p></td><td><p>Intravenous</p></td><td><p>15 to 30&nbsp;minutes</p></td></tr><tr><td><p>Oral</p></td><td><p>30 to 60&nbsp;minutes</p></td></tr><tr><td><p><strong>Glucocorticoid<sup>&Dagger;</sup></strong></p></td><td><p>Dexamethasone (20&nbsp;mg) or equivalent</p></td><td><p>Intravenous</p></td><td><p>60 to 120&nbsp;minutes</p></td></tr><tr><td><p><strong>Glucocorticoid</strong><sup>+</sup></p></td><td><p>Dexamethasone (10&nbsp;mg) or equivalent</p></td><td><p>Intravenous</p></td><td><p>45 to 60&nbsp;minutes</p></td></tr><tr><td colspan="4"><p>*&nbsp;&nbsp;&nbsp; Required at all doses.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; Required at initial dose (Week&nbsp;1, Day&nbsp;1) or at the next subsequent dose in the event of an IRR.</p><p><sup>+</sup>&nbsp;&nbsp; Required at second dose (Week&nbsp;1, Day&nbsp;2); optional for subsequent doses.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>There is no relevant use of amivantamab in the paediatric population in the treatment of non‑small cell lung cancer.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No dose adjustments are necessary (see section&nbsp;4.8, section&nbsp;5.1, and section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em><u>Renal impairment</u></em></p><p>No formal studies of amivantamab in patients with renal impairment have been conducted. Based on population pharmacokinetic (PK) analyses, no dose adjustment is necessary for patients with mild or moderate renal impairment. Caution is required in patients with severe renal impairment as amivantamab has not been studied in this patient population (see section&nbsp;5.2). If treatment is started, patients should be monitored for adverse reactions with dose modifications per the recommendations above.</p><p><em>&nbsp;</em></p><p><em><u>Hepatic impairment</u></em></p><p>No formal studies of amivantamab in patients with hepatic impairment have been conducted. Based on population PK analyses, no dose adjustment is necessary for patients with mild hepatic impairment. Caution is required in patients with moderate or severe hepatic impairment as amivantamab has not been studied in this patient population (see section&nbsp;5.2). If treatment is started, patients should be monitored for adverse reactions with dose modifications per the recommendations above.</p><p><em>&nbsp;</em></p><p><u>Method of administration</u></p><p>Rybrevant is for intravenous use. It is administered as an intravenous infusion following dilution with sterile 5% glucose solution or sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection. Rybrevant must be administered with in‑line filtration.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section&nbsp;6.6.</p><p>&nbsp;</p><p><em><u>Infusion rates</u></em></p><p>Following dilution, the infusion should be administered intravenously at the infusion rates presented in Table&nbsp;5 or 6 below. Due to the frequency of IRRs at the first dose, amivantamab should be infused via a peripheral vein at Week&nbsp;1 and Week&nbsp;2; infusion via a central line may be administered for subsequent weeks when the risk of IRR is lower (see section&nbsp;6.6). It is recommended for the first dose to be prepared as close to administration as possible to maximise the likelihood of completing the infusion in the event of an IRR.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion rates for Rybrevant every 3&nbsp;weeks</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Body weight less than 80&nbsp;kg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(per 250&nbsp;mL bag)</strong></p></td><td style="vertical-align:top"><p><strong>Initial infusion rate</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent infusion rate<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;1 (split dose infusion)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;1</em></p></td><td style="vertical-align:top"><p>350&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>75&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;2</em></p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td style="vertical-align:top"><p>33&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;2</strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>65&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;3</strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>85&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;4</strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent weeks</strong><sup>*</sup></p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Body weight greater than or equal to 80&nbsp;kg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(per 250</strong>&nbsp;<strong>mL bag)</strong></p></td><td style="vertical-align:top"><p><strong>Initial infusion rate</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent infusion rate<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;1 (split dose infusion)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1<em> Day&nbsp;1</em></p></td><td style="vertical-align:top"><p>350&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>75&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;2</em></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td style="vertical-align:top"><p>25&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;2</strong></p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>65&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;3</strong></p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>85&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;4</strong></p></td><td style="vertical-align:top"><p>1750&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent weeks</strong><sup>*</sup></p></td><td style="vertical-align:top"><p>2100&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp; Starting at Week&nbsp;7, patients are dosed every 3&nbsp;weeks.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Increase the initial infusion rate to the subsequent infusion rate after 2&nbsp;hours in the absence of infusion‑related reactions.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion rates for Rybrevant </strong><strong>every 2&nbsp;weeks</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Body weight less than 80&nbsp;kg</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(per 250&nbsp;mL bag)</strong></p></td><td style="vertical-align:top"><p><strong>Initial infusion rate</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent infusion rate<sup>&Dagger;</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;1 (split dose infusion)</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;1</em></p></td><td style="vertical-align:top"><p>350&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>75&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;2</em></p></td><td style="vertical-align:top"><p>700&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>75&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong>&nbsp;<strong>2</strong></p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>85&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent</strong> <strong>weeks<sup>*</sup></strong></p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Body weight greater than or equal to 80&nbsp;kg</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(per 250&nbsp;mL bag)</strong></p></td><td style="vertical-align:top"><p><strong>Initial infusion rate</strong></p></td><td style="vertical-align:top"><p><strong>Subsequent infusion rate<sup>&Dagger;</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;1 (split dose infusion)</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;1</em></p></td><td style="vertical-align:top"><p>350&nbsp;mg</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>75&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;1 <em>Day&nbsp;2</em></p></td><td style="vertical-align:top"><p>1050&nbsp;mg</p></td><td style="vertical-align:top"><p>35&nbsp;mL/hr</p></td><td style="vertical-align:top"><p>50&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;2</strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>65&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week&nbsp;3</strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>85&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Subsequent</strong> <strong>weeks<sup>*</sup></strong></p></td><td style="vertical-align:top"><p>1400&nbsp;mg</p></td><td colspan="2" style="vertical-align:top"><p>125&nbsp;mL/hr</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp; After Week&nbsp;5, patients are dosed every 2&nbsp;weeks.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; Increase the initial infusion rate to the subsequent infusion rate after 2&nbsp;hours in the absence of IRRs.</p></td><td><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infusion‑related reactions</u></p><p>Infusion‑related reactions commonly occurred in patients treated with amivantamab (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Prior to initial infusion (Week&nbsp;1), antihistamines, antipyretics, and glucocorticoids should be administered to reduce the risk of IRRs. For subsequent doses, antihistamines and antipyretics should be administered. The initial infusion should be administered in split doses on Week&nbsp;1, Day&nbsp;1 and 2.</p><p>&nbsp;</p><p>Patients should be treated in a setting with appropriate medical support to treat IRRs. Infusions should be interrupted at the first sign of IRRs of any severity and post‑infusion medicinal products should be administered as clinically indicated. Upon resolution of symptoms, the infusion should be resumed at 50% of the previous rate. For recurrent Grade&nbsp;3 or Grade&nbsp;4 IRRs, Rybrevant should be permanently discontinued (see section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p><u>Interstitial lung disease</u></p><p>Interstitial lung disease (ILD) or ILD‑like adverse reactions (e.g., pneumonitis) have been reported in patients treated with amivantamab (see section&nbsp;4.8). Patients should be monitored for symptoms indicative of ILD/pneumonitis (e.g., dyspnoea, cough, fever). If symptoms develop, treatment with Rybrevant should be interrupted pending investigation of these symptoms. Suspected ILD or ILD‑like adverse reactions should be evaluated and appropriate treatment should be initiated as necessary. Rybrevant should be permanently discontinued in patients with confirmed ILD or ILD-like adverse reactions (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Skin and nail reactions</u></p><p>Rash (including dermatitis acneiform), pruritus and dry skin occurred in patients treated with amivantamab (see section&nbsp;4.8). Patients should be instructed to limit sun exposure during and for 2&nbsp;months after Rybrevant therapy. Protective clothing and use of broad‑spectrum UVA/UVB sunscreen are advisable. Alcohol‑free emollient cream is recommended for dry areas. A prophylactic approach to rash prevention should be considered. If skin reactions develop, topical corticosteroids and topical and/or oral antibiotics should be administered. For Grade&nbsp;3 or poorly‑tolerated Grade&nbsp;2 events, systemic antibiotics and oral steroids should also be administered. Patients presenting with severe rash that has an atypical appearance or distribution or lack improvement within 2&nbsp;weeks should be referred promptly to a dermatologist. Rybrevant should be dose reduced, interrupted, or permanently discontinued based on severity (see section&nbsp;4.2)<em>.</em></p><p><em>&nbsp;</em></p><p>Toxic epidermal necrolysis (TEN) has been reported. Treatment with this medicinal product should be discontinued if TEN is confirmed.</p><p><em>&nbsp;</em></p><p><u>Eye disorders</u></p><p>Eye disorders, including keratitis, occurred in patients treated with amivantamab (see section&nbsp;4.8). Patients presenting with worsening eye symptoms should promptly be referred to an ophthalmologist and should discontinue use of contact lenses until symptoms are evaluated. For dose modifications for Grade&nbsp;3 or 4 eye disorders, see section&nbsp;4.2<em>.</em></p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, that is to say essentially &ldquo;sodium‑free&rdquo;. This medicinal product may be diluted in sodium chloride 9&nbsp;mg/mL (0.9%) solution for infusion. This should be taken into consideration for patients on a controlled sodium diet (see section&nbsp;6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No drug interaction studies have been performed. As an IgG1 monoclonal antibody, renal excretion and hepatic enzyme‑mediated metabolism of intact amivantamab are unlikely to be major elimination routes. As such, variations in drug‑metabolising enzymes are not expected to affect the elimination of amivantamab. Due to the high affinity to a unique epitope on EGFR and MET, amivantamab is not anticipated to alter drug‑metabolising enzymes.</p><p>&nbsp;</p><p><u>Vaccines</u></p><p>No clinical data are available on the efficacy and safety of vaccinations in patients taking amivantamab. Avoid the use of live or live‑attenuated vaccines while patients are taking amivantamab.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child‑bearing potential/Contraception</u></p><p>Women of child‑bearing potential should use effective contraception during and for 3&nbsp;months after cessation of amivantamab treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no human data to assess the risk of amivantamab use during pregnancy. No animal reproductive studies were conducted to inform a drug‑associated risk. Administration of EGFR and MET inhibitor molecules in pregnant animals resulted in an increased incidence of impairment of embryo‑foetal development, embryo lethality, and abortion. Therefore, based on its mechanism of action and findings in animal models, amivantamab could cause foetal harm when administered to a pregnant woman. Amivantamab should not be given during pregnancy unless the benefit of treatment of the woman is considered to outweigh potential risks to the foetus. If the patient becomes pregnant while taking this medicinal product the patient should be informed of the potential risk to the foetus (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>It is unknown whether amivantamab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards. A risk to the breast-fed child cannot be excluded during this short period just after birth, although IgGs are likely to be degraded in the gastrointestinal tract of the breast‑fed child and not absorbed. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from amivantamab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effect of amivantamab on human fertility. Effects on male and female fertility have not been evaluated in animal studies.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rybrevant may have moderate influence on the ability to drive and use machines. Please see section&nbsp;4.8 (e.g., dizziness, fatigue, visual impairment). If patients experience treatment‑related symptoms, including vision‑related adverse reactions, affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1 Adverse reactions:</strong></p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>In the dataset of amivantamab as monotherapy (N=380), the most frequent adverse reactions in all grades were rash (76%), infusion‑related reactions (67%), nail toxicity (47%), hypoalbuminaemia (31%), oedema (26%), fatigue (26%), stomatitis (24%), nausea (23%), and constipation (23%). Serious adverse reactions included ILD (1.3%), IRR (1.1%), and rash (1.1%). Three percent of patients discontinued Rybrevant due to adverse reactions. The most frequent adverse reactions leading to treatment discontinuation were IRR (1.1%), ILD (0.5%), and nail toxicity (0.5%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table&nbsp;7 summarises the adverse drug reactions that occurred in patients receiving amivantamab as monotherapy.</p><p>&nbsp;</p><p>The data reflects exposure to amivantamab in 380&nbsp;patients with locally advanced or metastatic non‑small cell lung cancer after failure of platinum‑based chemotherapy. Patients received amivantamab 1050&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 1400&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg). The median exposure to amivantamab was 4.1&nbsp;months (range: 0.0 to 39.7&nbsp;months).</p><p>&nbsp;</p><p>Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10000 to &lt;&nbsp;1/1000); very rare (&lt;&nbsp;1/10000); and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in patients receiving amivantamab as monotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p>Adverse reaction</p></td><td><p><strong>Frequency</strong></p><p><strong>category</strong></p></td><td style="vertical-align:top"><p><strong>Any Grade (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4 (%)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminaemia* (see section&nbsp;5.1)</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.3<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness*</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.3<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy<sup>a</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Headache<sup> b</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment*</p></td><td rowspan="3" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Growth of eyelashes*</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Other eye disorders*</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Keratitis</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Uveitis</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Interstitial lung disease*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td rowspan="5" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis*</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain*</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.8<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhoids</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.5<sup>&dagger;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash*</p></td><td rowspan="4" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>76</p></td><td style="vertical-align:top"><p>3<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nail toxicity*</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>2<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Dry skin*</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3<sup>&dagger;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup> c</sup></p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.3<sup>&dagger;</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oedema*</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.8<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue*</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.8<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup> d</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:103%"><tbody><tr><td style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp; Grouped terms</p><p>&dagger;&nbsp;&nbsp;&nbsp; Grade&nbsp;3 events only</p><p><sup>a</sup><sup> &nbsp;&nbsp;&nbsp;&nbsp;</sup>Peripheral neuropathy: hypoesthesia, neuralgia, paresthesia, peripheral sensory neuropathy</p><p><sup>b</sup>&nbsp;&nbsp; Headache: headache, migraine</p><p><sup>c</sup>&nbsp;&nbsp; Musculoskeletal pain: arthralgia&nbsp;</p><p><sup>d</sup>&nbsp; Hemorrhage: epistaxis</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>In the dataset of amivantamab in combination with carboplatin and pemetrexed (N=301), the most frequent adverse reactions in all grades were rash (83%), neutropenia (57%), nail toxicity (53%), infusion related reactions (51%), fatigue (43%), stomatitis (39%), nausea (43%), thrombocytopenia (40%), constipation (40%), oedema (40%), decreased appetite (33%), hypoalbuminaemia (32%), alanine aminotransferase increased (26%), aspartate aminotransferase increased (23%), vomiting (22%), and hypokalaemia (20%). Serious adverse reactions included rash (2.7%), venous thromboembolism (2.3%), thrombocytopenia (2.3%) and ILD (2.0%). Eight percent of patients discontinued Rybrevant due to adverse reactions. The most frequent adverse reactions leading to treatment discontinuation were IRR (2.7%), rash (2.3%), ILD (2.3%), and nail toxicity (1.0%).</p><p>&nbsp;</p><p>Table&nbsp;8 summarises the adverse drug reactions that occurred in patients receiving amivantamab in combination with chemotherapy.</p><p>&nbsp;</p><p>The data reflects exposure to amivantamab in combination with carboplatin and pemetrexed in 301&nbsp;patients with locally advanced or metastatic non‑small cell lung cancer. Patients received amivantamab 1400&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 1750&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) weekly for 4&nbsp;weeks. Starting at Week&nbsp;7, patients received amivantamab 1750&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 2100&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) every 3&nbsp;weeks. The median exposure to amivantamab in combination with carboplatin and pemetrexed was 7.7&nbsp;months (range: 0.0 to 28.1&nbsp;months).</p><p>&nbsp;</p><p>Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10000 to &lt;&nbsp;1/1000); very rare (&lt;&nbsp;1/10000); and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in patients receiving amivantamab in combination with </strong><strong>carboplatin and pemetrexed</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p>Adverse reaction</p></td><td><p><strong>Frequency category</strong></p></td><td style="vertical-align:top"><p><strong>Any Grade (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3-4 (%)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td rowspan="5" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminaemia*</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>6.6</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Venous thromboembolism*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other eye disorders*</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment*</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Growth of eyelashes</p></td><td rowspan="3" style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Keratitis</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Uveitis</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Interstitial lung disease*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td rowspan="5" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis*</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>3.0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain*</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Haemorrhoids</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>4.3</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash*</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Nail toxicity*</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>4.3</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin*</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue*</p></td><td rowspan="3" style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>4.7</p></td></tr><tr><td style="vertical-align:top"><p>Oedema*</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>3.0</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Infusion‑related reactions</u></em></p><p>In patients treated with amivantamab monotherapy, infusion‑related reactions occurred in 67% of patients. Ninety‑eight percent of IRRs were Grade&nbsp;1‑2. Ninety‑nine percent of IRRs occurred at the first infusion with a median time to onset of 60&nbsp;minutes, and the majority occurring within 2&nbsp;hours of infusion start. The most frequent signs and symptoms include chills, dyspnoea, nausea, flushing, chest discomfort, hypotension, fever and vomiting (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In patients treated with amivantamab in combination with carboplatin and pemetrexed, infusion‑related reactions occurred in 50% of patients. Greater than 94% of IRRs were Grade&nbsp;1‑2. A majority of IRRs occurred at the first infusion with a median time to onset of 60&nbsp;minutes (range 0‑7&nbsp;hours), and the majority occurring within 2&nbsp;hours of infusion start. Occasionally an IRR can occur at re-initiation of amivantamab after prolonged dose interruptions of more than 6&nbsp;weeks.</p><p>&nbsp;</p><p><em><u>Interstitial lung disease</u></em></p><p>Interstitial lung disease or ILD‑like adverse reactions have been reported with the use of amivantamab as well as with other EGFR inhibitors. Interstitial lung disease or pneumonitis was reported in 2.6% of patients treated with amivantamab monotherapy and 2.3 % of patients treated with amivantamab in combination with carboplatin and pemetrexed. Patients with a medical history of ILD, drug‑induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD were excluded from the clinical study (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Skin and nail reactions</u></em></p><p>Rash (including dermatitis acneiform), pruritus, and dry skin occurred in 86% of patients treated with amivantamab alone. Most cases were Grade&nbsp;1 or 2, with Grade&nbsp;3 rash events occurring in 3% of patients. Rash leading to amivantamab discontinuation occurred in 0.3% of patients. Rash usually developed within the first 4&nbsp;weeks of therapy, with a median time to onset of 14&nbsp;days. Nail toxicity occurred in patients treated with amivantamab. Most events were Grade&nbsp;1 or 2, with Grade&nbsp;3 nail toxicity occurring in 1.8% of patients.</p><p>&nbsp;</p><p>Rash (including dermatitis acneiform), occurred in 83% of patients treated with amivantamab in combination with carboplatin and pemetrexed. Most cases were Grade&nbsp;1 or 2, with Grade&nbsp;3 rash events occurring in 14% of patients. Rash leading to amivantamab discontinuation occurred in 2.3% of patients. Rash usually developed within the first 4&nbsp;weeks of therapy, with a median time to onset of 14&nbsp;days. Nail toxicity occurred in patients treated with amivantamab in combination with carboplatin and pemetrexed. Most events were Grade&nbsp;1 or 2, with Grade&nbsp;3 nail toxicity occurring in 4.3% of patients (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Eye disorders</u></em></p><p>Eye disorders, including keratitis (0.5%), occurred in 9% of patients treated with amivantamab alone. Other reported adverse reactions included growth of eyelashes, visual impairment, and other eye disorders. All events were Grade&nbsp;1‑2.</p><p>&nbsp;</p><p>Eye disorders, including keratitis (0.3%), occurred in 11% of patients treated with amivantamab in combination with carboplatin and pemetrexed. Other reported adverse reactions included growth of eyelashes, visual impairment, uveitis, and other eye disorders. All events were Grade&nbsp;1‑2 (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><u>Other special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>There are limited clinical data with amivantamab in patients 75&nbsp;years of age or over (see section&nbsp;5.1). No overall differences in safety were observed between patients &ge;&nbsp;65&nbsp;years of age and patients &lt;&nbsp;65&nbsp;years of age.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>As with all therapeutic proteins, there is the potential for immunogenicity. In clinical studies of patients with locally advanced or metastatic NSCLC treated with amivantamab, 4 of the 865 (0.5%) participants who were treated with Rybrevant and evaluable for the presence of anti‑drug antibodies (ADA), tested positive for treatment‑emergent anti‑amivantamab antibodies. There was no evidence of an altered pharmacokinetic, efficacy, or safety profile due to anti‑amivantamab antibodies.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p><strong>4.8.2: Clinical Studies Experience (upon request from any regulatory Authority in GCC)</strong></p><p>&nbsp;</p><p><u>Clinical Trials Experience</u></p><p><em>&nbsp;</em></p><p>Serious adverse reactions occurred in 30% of patients who received RYBREVANT. Serious adverse reactions in &ge; 2% of patients included pulmonary embolism, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.</p><p>&nbsp;</p><p>Permanent discontinuation of RYBREVANT due to an adverse reaction occurred in 11% of patients. Adverse reactions resulting in permanent discontinuation of RYBREVANT in &ge;1% of patients were pneumonia, IRR, pneumonitis/ILD, dyspnea, pleural effusion, and rash.</p><p>&nbsp;</p><p>The most common adverse reactions (&ge; 20%) were rash, IRR, paronychia, musculoskeletal pain, dyspnea, nausea, fatigue, edema, stomatitis, cough, constipation, and vomiting. The most common Grade 3 to 4 laboratory abnormalities (&ge; 2%) were decreased lymphocytes, decreased albumin, decreased phosphate, decreased potassium, increased glucose, increased alkaline phosphatase, increased gamma-glutamyl transferase, and decreased sodium.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>To report any side effect(s):</u></em></p><p><strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp; &nbsp;SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p><em>&ndash; </em><em>Please</em><em> </em><em>contact</em><em> </em><em>the</em><em> </em><em>relevant</em><em> </em><em>competent</em><em> </em><em>authority.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No maximum tolerated dose has been determined in a clinical study in which patients received up to 2100&nbsp;mg administered intravenously. There is no known specific antidote for amivantamab overdose. In the event of an overdose, treatment with Rybrevant should be stopped, the patient should be monitored for any signs or symptoms of adverse events and appropriate general supportive measures should be instituted immediately until clinical toxicity has diminished or resolved.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Monoclonal antibodies and antibody drug conjugates, ATC code: L01FX18.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Amivantamab is a low‑fucose, fully‑human IgG1‑based EGFR‑MET bispecific antibody with immune cell‑directing activity that targets tumours with activating EGFR mutations such as Exon&nbsp;19 deletions, L858R substitution, and Exon&nbsp;20 insertion mutations. Amivantamab binds to the extracellular domains of EGFR and MET.</p><p>&nbsp;</p><p>Amivantamab disrupts EGFR and MET signalling functions through blocking ligand binding and enhancing degradation of EGFR and MET, thereby preventing tumour growth and progression. The presence of EGFR and MET on the surface of tumour cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody‑dependent cellular cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>&nbsp;</em></p><p><em><u>Albumin</u></em></p><p>Amivantamab decreased serum albumin concentration, a pharmacodynamic effect of MET inhibition, typically during the first 8&nbsp;weeks (see section&nbsp;4.8); thereafter, albumin concentration stabilised for the remainder of amivantamab treatment.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Previously treated NSCLC with EGFR Exon&nbsp;19 deletions or Exon&nbsp;21 L858R substitution mutations (MARIPOSA‑2)</u></em></p><p>MARIPOSA‑2 is a randomised (2:2:1) open‑label, multicentre Phase&nbsp;3 study in patients with locally advanced or metastatic NSCLC with EGFR Exon&nbsp;19 deletions or Exon&nbsp;21 L858R substitution mutations (mutation testing could have been performed at or after the time of locally advanced or metastatic disease diagnosis. Testing did not need to be repeated at the time of study entry once EGFR mutation status was previously established) after failure of prior therapy including a third‑generation EGFR tyrosine kinase inhibitor (TKI). A total of 657&nbsp;patients were randomised in the study, of which 263&nbsp;received carboplatin and pemetrexed (CP); and 131 which received Rybrevant in combination with carboplatin and pemetrexed (Rybrevant‑CP)<em>.</em> Additionally, 236&nbsp;patients were randomised to receive Rybrevant in combination with lazertinib, carboplatin, and pemetrexed in a separate arm of the study. Rybrevant was administered intravenously at 1400&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 1750&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) once weekly through 4&nbsp;weeks, then every 3&nbsp;weeks with a dose of 1750&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 2100&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) starting at Week&nbsp;7 until disease progression or unacceptable toxicity. Carboplatin was administered intravenously at area under the concentration‑time curve 5&nbsp;mg/mL per minute (AUC 5) once every 3&nbsp;weeks, for up to 12&nbsp;weeks. Pemetrexed was administered intravenously at 500&nbsp;mg/m<sup>2</sup> on once every 3&nbsp;weeks until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Patients were stratified by osimertinib line of therapy (first‑line or second‑line), prior brain metastases (yes or no), and Asian race (yes or no).</p><p>&nbsp;</p><p>Of the 394&nbsp;patients randomised to the Rybrevant‑CP arm or CP arm, the median age was 62 (range: 31‑85) years, with 38% of the patients &ge;&nbsp;65&nbsp;years of age; 60% were female; and 48% were Asian and 46% were White. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 (40%) or 1 (60%); 66% never smoked; 45% had history of brain metastasis, and 92% had Stage&nbsp;IV cancer at initial diagnosis.</p><p>&nbsp;</p><p>Rybrevant in combination with carboplatin and pemetrexed demonstrated a statistically significant improvement in progression‑free survival (PFS) compared to carboplatin and pemetrexed, with a HR of 0.48 (95% CI: 0.36, 0.64; p&lt;0.0001). At the time of the second interim analysis for OS, with a median follow‑up of approximately 18.6&nbsp;months for Rybrevant‑CP and approximately 17.8 months for CP, the OS HR was 0.73 (95%CI: 0.54, 0.99; p=0.0386). This was not statistically significant (tested at a prespecified significance level of 0.0142).</p><p>&nbsp;</p><p>Efficacy results are summarised in Table&nbsp;9.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;9:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results in MARIPOSA-2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Rybrevant+</strong></p><p><strong>carboplatin+</strong></p><p><strong>pemetrexed</strong></p><p><strong>(N=131)</strong></p></td><td style="vertical-align:bottom"><p><strong>carboplatin+</strong></p><p><strong>pemetrexed</strong></p><p><strong>(N=263)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-free survival (PFS)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>74 (57)</p></td><td style="vertical-align:top"><p>171 (65)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>6.3 (5.6, 8.4)</p></td><td style="vertical-align:top"><p>4.2 (4.0, 4.4)</p></td></tr><tr><td><p>HR (95% CI); p-value</p></td><td colspan="2"><p>0.48 (0.36, 0.64); p&lt;0.0001</p></td></tr><tr><td colspan="3"><p><strong>Overall survival (OS)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td><p>65 (50)</p></td><td><p>143 (54)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td><p>17.7 (16.0, 22.4)</p></td><td><p>15.3 (13.7, 16.8)</p></td></tr><tr><td><p>HR (95% CI); p‑value<strong><sup>b</sup></strong></p></td><td colspan="2"><p>0.73 (0.54, 0.99); p=0.0386</p></td></tr><tr><td colspan="3"><p><strong>Objective response rate<sup>a</sup></strong></p></td></tr><tr><td><p>ORR, % (95% CI)</p></td><td><p>64% (55%, 72%)</p></td><td><p>36% (30%, 42%)</p></td></tr><tr><td><p>Odds Ratio (95% CI); p-value</p></td><td colspan="2"><p>3.10 (2.00, 4.80); p&lt;0.0001</p></td></tr><tr><td colspan="3"><p><strong>Duration of response (DOR)</strong><strong><sup> a</sup></strong></p></td></tr><tr><td><p>Median (95% CI), months</p></td><td><p>6.90 (5.52, NE)</p></td><td style="vertical-align:top"><p>5.55 (4.17, 9.56)</p></td></tr><tr><td><p>Patients with DOR &ge;&nbsp;6&nbsp;months</p></td><td><p>31.9%</p></td><td style="vertical-align:top"><p>20.0%</p></td></tr><tr><td colspan="3"><p>CI = Confidence Interval</p><p>PFS and ORR results are from data cut-off 10 July-2023 when hypothesis testing and final analysis for these endpoints was performed. OS results are from data cut-off 26 April 2024 from the second interim OS analysis.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; BICR‑assessed</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; The p-value is compared to a 2-sided significance level of 0.0142. Thus the OS results are not significant as of the second interim analysis.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curve of PFS in previously treated NSCLC patients by BICR assessment</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_152" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:453.6pt;height:240pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="320" alt="" vspace="0" hspace="0" border="0" style="width:605px;height:320px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>The PFS benefit of Rybrevant‑CP compared to CP was consistent across all the predefined subgroups analysed, including ethnicity, age, gender, smoking history, and CNS metastases status at study entry.</p><p>&nbsp;</p><p><strong>Figure&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curve of OS in previously treated NSCLC patients</strong></p><p><em><u>&nbsp;</u></em></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1027"
 type="#_x0000_t75" style='width:453.6pt;height:255pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="340" alt="" vspace="0" hspace="0" border="0" style="width:605px;height:340px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image004.png" /></p><p><em>&nbsp;</em></p><p><em>Intracranial metastases efficacy data</em></p><p>Patients with asymptomatic or previously treated and stable intracranial metastases were eligible to be randomised in MARIPOSA‑2. Treatment with Rybrevant-CP was associated with a numeric increase in intracranial ORR (23.3% for Rybrevant-CP versus 16.7% for CP, odds ratio of 1.52; 95% CI (0.51, 4.50), and intracranial DOR (13.3 months; 95% CI (1.4, NE) in the Rybrevant-CP arm compared with 2.2&nbsp;months; 95% CI (1.4, NE) in the CP arm). The median follow-up for Rybrevant-CP was approximately 18.6 months.</p><p>&nbsp;</p><p><em><u>Previously-untreated non-small cell lung cancer (NSCLC)</u></em><strong><u> </u></strong><em><u>with Exon&nbsp;20 insertion mutations (PAPILLON)</u></em></p><p>PAPILLON is a randomised, open‑label, multicentre Phase&nbsp;3 study comparing treatment with Rybrevant in combination with carboplatin and pemetrexed to chemotherapy alone (carboplatin and pemetrexed) in patients with treatment‑na&iuml;ve, locally advanced or metastatic NSCLC with activating EGFR Exon&nbsp;20 insertion mutations. Tumour tissue (92.2%) and/or plasma (7.8%) samples for all 308&nbsp;patients were tested locally to determine EGFR Exon&nbsp;20 insertion mutation status using next generation sequencing (NGS) in 55.5% of patients and/or polymerase chain reaction (PCR) in 44.5% of patients. Central testing was also performed using the AmoyDx&reg; LC10 tissue test, Thermo Fisher Oncomine Dx Target Test, and the Guardant 360&reg; CDx plasma test.</p><p>&nbsp;</p><p>Patients with brain metastases at screening were eligible for participation once they were definitively treated, clinically stable, asymptomatic, and off corticosteroid treatment for at least 2&nbsp;weeks prior to randomisation.</p><p>&nbsp;</p><p>Rybrevant was administered intravenously at 1400&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 1750&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) once weekly through 4&nbsp;weeks, then every 3&nbsp;weeks with a dose of 1750&nbsp;mg (for patients &lt;&nbsp;80&nbsp;kg) or 2100&nbsp;mg (for patients &ge;&nbsp;80&nbsp;kg) starting at Week&nbsp;7 until disease progression or unacceptable toxicity. Carboplatin was administered intravenously at area under the concentration-time curve 5&nbsp;mg/mL per minute (AUC 5) once every 3&nbsp;weeks, for up to 12&nbsp;weeks. Pemetrexed was administered intravenously at 500&nbsp;mg/m<sup>2</sup> on once every 3&nbsp;weeks until disease progression or unacceptable toxicity. Randomisation was stratified by ECOG performance status (0 or 1), and prior brain metastases (yes or no). Patients randomised to the carboplatin and pemetrexed arm who had confirmed disease progression were permitted to cross over to receive Rybrevant monotherapy.</p><p>A total of 308&nbsp;subjects were randomised (1:1) to Rybrevant in combination with carboplatin and pemetrexed (N=153) or carboplatin and pemetrexed (N=155). The median age was 62 (range: 27 to 92) years, with 39% of the subjects &ge;&nbsp;65&nbsp;years of age; 58% were female; and 61% were Asian and 36% were White. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 (35%) or 1 (64%); 58% never smoked; 23% had history of brain metastasis and 84% had Stage&nbsp;IV cancer at initial diagnosis.</p><p>&nbsp;</p><p>The primary endpoint for PAPILLON was PFS, as assessed by BICR. The median follow‑up was14.9 months (range: 0.3 to 27.0).</p><p>&nbsp;</p><p>Efficacy results are summarised in Table&nbsp;10.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;10:&nbsp;&nbsp;&nbsp; Efficacy results in PAPILLON</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Rybrevant +</strong></p><p><strong>carboplatin+</strong></p><p><strong>pemetrexed</strong></p><p><strong>(N=153)</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>carboplatin+</strong></p><p><strong>pemetrexed</strong></p><p><strong>(N=155)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression-free survival (PFS)<sup> a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events</p></td><td style="vertical-align:top"><p>84 (55%)</p></td><td colspan="2" style="vertical-align:top"><p>132 (85%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>11.4 (9.8, 13.7)</p></td><td colspan="2" style="vertical-align:top"><p>6.7 (5.6, 7.3)</p></td></tr><tr><td><p>HR (95% CI); p‑value</p></td><td colspan="3"><p>0.395 (0.29, 0.52); p&lt;0.0001</p></td></tr><tr><td colspan="4"><p><strong>Objective response rate<sup>a, b</sup></strong></p></td></tr><tr><td><p>ORR, % (95% CI)</p></td><td><p>73% (65%, 80%)</p></td><td colspan="2"><p>47% (39%, 56%)</p></td></tr><tr><td><p>Odds ratio (95% CI); p‑value</p></td><td colspan="2"><p>3.0 (1.8, 4.8); p&lt;0.0001</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Complete response</p></td><td><p>3.9%</p></td><td colspan="2" style="vertical-align:top"><p>0.7%</p></td></tr><tr><td><p>Partial response</p></td><td><p>69%</p></td><td colspan="2" style="vertical-align:top"><p>47%</p></td></tr><tr><td colspan="4"><p><strong>Overall survival (OS)<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events</p></td><td style="vertical-align:top"><p>40</p></td><td colspan="2" style="vertical-align:top"><p>52</p></td></tr><tr><td style="vertical-align:top"><p>Median OS, months (95% CI)</p></td><td style="vertical-align:top"><p>NE (28.3, NE)</p></td><td colspan="2" style="vertical-align:top"><p>28.6 (24.4, NE)</p></td></tr><tr><td><p>HR (95% CI); p‑value</p></td><td colspan="3"><p>0.756 (0.50, 1.14); p=0.1825</p></td></tr><tr><td colspan="4"><p>CI = confidence interval</p><p>NE = not estimable</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Blinded Independent Central Review by RECIST v1.1</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimate.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on the results of an updated OS with median follow-up of 20.9&nbsp;months. The OS analysis was not adjusted for the potentially confounding effects of crossover (78 [50.3%] patients on the carboplatin + pemetrexed arm who received subsequent Rybrevant monotherapy treatment).</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curve of PFS in previously untreated NSCLC patients by BICR assessment</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_7" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.6pt;
 height:214.8pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="286" alt="" vspace="0" hspace="0" border="0" style="width:605px;height:286px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image006.png" /></p><p>&nbsp;</p><p>The PFS benefit of Rybrevant in combination with carboplatin and pemetrexed compared to carboplatin and pemetrexed was consistent across all the predefined subgroups of brain metastases at study entry (yes or no), age (&lt;&nbsp;65 or &ge;&nbsp;65), sex (male or female), race (Asian or non‑Asian), weight (&lt;&nbsp;80&nbsp;kg or &ge;&nbsp;80&nbsp;kg), ECOG performance status (0 or 1), and smoking history (yes or no).</p><p>&nbsp;</p><p><strong>Figure&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier curve of OS in previously untreated NSCLC patients by BICR assessment</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_17"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;height:240pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="320" alt="" vspace="0" hspace="0" border="0" style="width:605px;height:320px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/2/msohtmlclip1/01/clip_image008.png" /></p><p>&nbsp;</p><p><em><u>Previously‑treated non-small cell lung cancer(NSCLC)</u></em><strong><u> </u></strong><em><u>with Exon&nbsp;20 insertion mutations (CHRYSALIS)</u></em></p><p>CHRYSALIS is a multicentre, open‑label, multi‑cohort study conducted to assess the safety and efficacy of Rybrevant in patients with locally advanced or metastatic NSCLC. Efficacy was evaluated in 114&nbsp;patients with locally advanced or metastatic NSCLC who had EGFR Exon&nbsp;20 insertion mutations, whose disease had progressed on or after platinum‑based chemotherapy, and who had a median follow‑up of 12.5&nbsp;months. Tumour tissue (93%) and/or plasma (10%) samples for all patients were tested locally to determine EGFR Exon&nbsp;20 insertion mutation status using next generation sequencing (NGS) in 46% of patients and/or polymerase chain reaction (PCR) in 41% of patients; for 4% of patients, the testing methods were not specified. Patients with untreated brain metastases or a history of ILD requiring treatment with prolonged steroids or other immunosuppressive agents within the last 2&nbsp;years were not eligible for the study. Rybrevant was administered intravenously at 1050&nbsp;mg for patients &lt;&nbsp;80&nbsp;kg or 1400&nbsp;mg for patients &ge;&nbsp;80&nbsp;kg once weekly for 4&nbsp;weeks, then every 2&nbsp;weeks starting at Week&nbsp;5 until loss of clinical benefit or unacceptable toxicity. The primary efficacy endpoint was investigator‑assessed overall response rate (ORR), defined as confirmed complete response (CR) or partial response (PR) based on RECIST v1.1. In addition, the primary endpoint was assessed by a blinded independent central review (BICR). Secondary efficacy endpoints included duration of response (DOR).</p><p>&nbsp;</p><p>The median age was 62 (range: 36&ndash;84) years, with 41% of the patients &ge;&nbsp;65&nbsp;years of age; 61% were female; and 52% were Asian and 37% were White. The median number of prior therapies was 2 (range: 1 to 7&nbsp;therapies). At baseline, 29% had Eastern Cooperative Oncology Group (ECOG) performance status of 0 and 70% had ECOG performance status of 1; 57% never smoked; 100% had Stage IV cancer; and 25% had previous treatment for brain metastases. Insertions in Exon&nbsp;20 were observed at 8&nbsp;different residues; the most common residues were A767 (22%), S768 (16%), D770 (12%), and N771 (11%).</p><p>&nbsp;</p><p>Efficacy results are summarised in Table&nbsp;11.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;11:&nbsp;&nbsp;&nbsp; Efficacy results in CHRYSALIS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Investigator assessment</strong></p><p><strong>(N=114)</strong></p></td></tr><tr><td><p><strong>Overall response rate<sup>a, b</sup> </strong>(95% CI)</p></td><td><p>37% (28%, 46%)</p></td></tr><tr><td><p>Complete response</p></td><td><p>0%</p></td></tr><tr><td><p>Partial response</p></td><td><p>37%</p></td></tr><tr><td colspan="2"><p><strong>Duration of response</strong></p></td></tr><tr><td><p>Median<sup>c</sup> (95% CI), months</p></td><td><p>12.5 (6.5, 16.1)</p></td></tr><tr><td><p>Patients with DOR &ge;&nbsp;6&nbsp;months</p></td><td><p>64%</p></td></tr><tr><td colspan="2"><p>CI = Confidence Interval</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Confirmed response</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; ORR and DOR results by investigator assessment were consistent with those reported by BICR assessment; ORR by BICR assessment was 43% (34%, 53%), with a 3% CR rate and a 40% PR rate, median DOR by BICR assessment was 10.8&nbsp;months (95% CI: 6.9, 15.0), and patients with DOR &ge;&nbsp;6&nbsp;months by BICR assessment was 55%.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on Kaplan‑Meier estimate.</p></td></tr></tbody></table><p>&nbsp;</p><p>Anti‑tumour activity was observed across studied mutation subtypes.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>No overall differences in effectiveness were observed between patients &ge;&nbsp;65&nbsp;years of age and patients &lt;&nbsp;65&nbsp;years of age.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Rybrevant in all subsets of the paediatric population in non‑small cell lung cancer (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on Rybrevant monotherapy data, amivantamab area under the concentration‑time curve (AUC<sub>1&nbsp;week</sub>) increases proportionally over a dose range from 350 to 1750&nbsp;mg.</p><p>&nbsp;</p><p>Based on simulations from the population pharmacokinetic model, AUC<sub>1 week</sub><sub> </sub>was approximately 2.8‑fold higher after the fifth dose for the 2‑week dosing regimen and 2.6‑fold higher after the fourth dose for the 3‑week dosing regimen. Steady‑state concentrations of amivantamab were reached by Week&nbsp;13 for both the 3‑week and 2‑week dosing regimen and the systemic accumulation was 1.9‑fold.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Based on the individual amivantamab PK parameter estimates in population PK analysis, the geometric mean (CV%) total volume of distribution, is 5.12 (27.8%) L, following administration of the recommended dose of Rybrevant.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Based on the individual amivantamab PK parameter estimates in population PK analysis, the geometric mean (CV%) linear clearance (CL) and terminal half‑life associated with linear clearance is 0.266 (30.4%) L/day and 13.7 (31.9%) days respectively.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No clinically meaningful differences in the pharmacokinetics of amivantamab were observed based on age (27‑87&nbsp;years).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No clinically meaningful effect on the pharmacokinetics of amivantamab was observed in patients with mild (60&nbsp;&le; creatinine clearance [CrCl] &lt;&nbsp;90&nbsp;mL/min) and moderate (29&nbsp;&le; CrCl &lt;&nbsp;60&nbsp;mL/min) renal impairment. The effect of severe renal impairment (15&nbsp;&le; CrCl &lt;&nbsp;29&nbsp;mL/min) on amivantamab pharmacokinetics is unknown.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Changes in hepatic function are unlikely to have any effect on the elimination of amivantamab since IgG1‑based molecules such as amivantamab are not metabolised through hepatic pathways.</p><p>&nbsp;</p><p>No clinically meaningful effect in the pharmacokinetics of amivantamab was observed based on mild hepatic impairment [(total bilirubin &le;&nbsp;ULN and AST &gt;&nbsp;ULN) or (ULN&nbsp;&lt; total bilirubin &le;&nbsp;1.5&nbsp;x&nbsp;ULN)]. The effect of moderate (total bilirubin 1.5 to 3&nbsp;times ULN) and severe (total bilirubin &gt;&nbsp;3&nbsp;times ULN) hepatic impairment on amivantamab pharmacokinetics is unknown.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The pharmacokinetics of Rybrevant in paediatric patients have not been investigated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>No animal studies have been performed to establish the carcinogenic potential of amivantamab. Routine genotoxicity and carcinogenicity studies are generally not applicable to biologic pharmaceuticals as large proteins cannot diffuse into cells and cannot interact with DNA or chromosomal material.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>No animal studies have been conducted to evaluate the effects on reproduction and foetal development; however, based on its mechanism of action, amivantamab can cause foetal harm or developmental anomalies. As reported in the literature, reduction, elimination, or disruption of embryo foetal or maternal EGFR signaling can prevent implantation, cause embryo foetal loss during various stages of gestation (through effects on placental development), cause developmental anomalies in multiple organs or early death in surviving foetuses. Similarly, knock out of MET or its ligand hepatocyte growth factor (HGF) was embryonic lethal due to severe defects in placental development, and foetuses displayed defects in muscle development in multiple organs. Human IgG1 is known to cross the placenta; therefore, amivantamab has the potential to be transmitted from the mother to the developing foetus.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate</p><p>L‑Histidine</p><p>L‑Histidine hydrochloride monohydrate</p><p>L‑Methionine</p><p>Polysorbate&nbsp;80 (E433)</p><p>Sucrose</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years

After dilution
Chemical and physical in use stability has been demonstrated for 10 hours at 15°C to 25°C in room light. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in use storage times and conditions are the responsibility of the user.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>7&nbsp;mL concentrate in a Type&nbsp;1 glass vial with an elastomeric closure and aluminium seal with a flip‑off cap containing 350&nbsp;mg amivantamab. Pack size of 1&nbsp;vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prepare the solution for intravenous infusion using aseptic technique as follows:</p><p>&nbsp;</p><p><u>Preparation</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Determine the dose required and the number of Rybrevant vials needed based on patient&rsquo;s baseline weight (see section&nbsp;4.2). Each vial contains 350&nbsp;mg of amivantamab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For every 2‑week dosing, patients &lt;&nbsp;80&nbsp;kg receive 1050&nbsp;mg and for patients &ge;&nbsp;80&nbsp;kg, 1400&nbsp;mg once weekly for a total of 4&nbsp;doses, then every 2&nbsp;weeks starting at Week&nbsp;5.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For every 3‑week dosing, patients &lt;&nbsp;80&nbsp;kg receive 1400&nbsp;mg once weekly for a total of 4&nbsp;doses, then 1750&nbsp;mg every 3&nbsp;weeks starting at Week&nbsp;7, and for patients &ge;&nbsp;80&nbsp;kg, 1750&nbsp;mg once weekly for a total of 4&nbsp;doses, then 2100&nbsp;mg every 3&nbsp;weeks starting at Week&nbsp;7.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check that the Rybrevant solution is colourless to pale yellow. Do not use if discolouration or visible particles are present.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw and then discard a volume of either 5% glucose solution or sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection from the 250&nbsp;mL infusion bag that is equal to the required volume of Rybrevant solution to be added (discard 7&nbsp;mL diluent from the infusion bag for each vial). Infusion bags must be made of polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE), or polyolefin blend (PP+PE).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw 7&nbsp;mL of Rybrevant from each vial needed then add it to the infusion bag. Each vial contains a 0.5&nbsp;mL overfill to ensure sufficient extractable volume. The final volume in the infusion bag should be 250&nbsp;mL. Discard any unused portion left in the vial.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently invert the bag to mix the solution. Do not shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect for particulate matter and discolouration prior to administration. Do not use if discolouration or visible particles are observed.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the diluted solution by intravenous infusion using an infusion set fitted with a flow regulator and with an in‑line, sterile, non‑pyrogenic, low protein‑binding polyethersulfone (PES) filter (pore size 0.22 or 0.2&nbsp;micrometer). Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), PVC, PP, or PE.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The administration set with filter must be primed with either 5% glucose solution or 0.9% sodium chloride solution prior to the initiation of each Rybrevant infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not infuse Rybrevant concomitantly in the same intravenous line with other agents.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The diluted solution should be administered within 10&nbsp;hours (including infusion time) at room temperature (15&deg;C to 25&deg;C) and in room light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Due to the frequency of IRRs at the first dose, amivantamab should be infused via a peripheral vein at Week&nbsp;1 and Week&nbsp;2; infusion via a central line may be administered for subsequent weeks when the risk of IRR is lower. See infusion rates in section&nbsp;4.2.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>This medicinal product is for single use only and any unused medicinal product that is not administered within 10&nbsp;hours should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag International NV
Turnhoutseweg 30
B 2340 Beerse
Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22 August 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>